中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 1
Jan.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(1): 69-74

Efficacy of stereotactic body radiotherapy combined with sintilimab and bevacizumab in treatment of unresectable hepatocellular carcinoma

DOI: 10.12449/JCH250111

  • Department of Radiation Oncology，Senior Department of Oncology，The Fifth Medical Center of PLA General Hospital，Beijing 100039，China

More Information
  • Corresponding author: DUAN Xuezhang， duanxuezhang2006@163.com （ORCID： 0000-0002-1941-9317）
  • Received Date: 2024-06-11
  • Accepted Date: 2024-09-04
  • Published Date: 2025-01-25
    Abstract
  •   Objective  To investigate the efficacy and safety of stereotactic body radiotherapy （SBRT） combined with sintilimab and bevacizumab in the treatment of patients with unresectable hepatocellular carcinoma （uHCC） and related prognostic factors.  Methods  A total of 42 patients with uHCC who underwent SBRT combined with sintilimab and bevacizumab in Department of Radiation Oncology， The Fifth Medical Centre of PLA General Hospital， from March to December 2022 were enrolled. The prescribed dose of planning target volume was 36‍ ‍—‍ ‍50 Gy in 5‍ ‍—‍ ‍6 fractions for continuous irradiation， followed by the regimen of sintilimab and bevacizumab. Each course of treatment was 3 weeks until the presence of tumor progression or serious adverse events. The Kaplan-Meier method was used to calculate overall survival （OS） rate and progression-free survival （PFS） rate， and the log-rank test was used for comparison between groups； the Cox proportional hazards model was used to investigate the influencing factors for prognosis.  Results  The median follow-up time was 21.6 months， with an objective response rate of 69%， a disease control rate of 85.7%， a median PFS of 10.0 months （95% confidence interval ［CI］： 6.7‍ ‍—‍ ‍13.0）， and a median OS of 23.3 months （95%CI： 14.7‍ ‍—‍ ‍31.8）. Most adverse events were grade 1‍ ‍—‍ ‍2 events， and there were no fatal adverse events. At 6‍ ‍—‍ ‍8 weeks after treatment， the AFP response group had a significantly better OS than the non-AFP response group （not reached vs 11.8 months， P=0.007）. The multivariate analysis showed that AFP response was associated with the good prognosis of patients （hazard ratio=0.31， 95%CI： 0.13‍ ‍—‍ ‍0.75， P=0.009）.  Conclusion  For patients with uHCC， SBRT combined with sintilimab and bevacizumab can improve survival with a manageable safety profile， and a >50% reduction in AFP at 6‍ ‍—‍ ‍8 weeks after treatment can be used as a potential prognostic indicator.

     

    • FullText(HTML)
  • loading
    • References(25)
  • [1]
    REIG M, FORNER A, RIMOLA J, et al. BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update[J]. J Hepatol, 2022, 76( 3): 681- 693. DOI: 10.1016/j.jhep.2021.11.018.
    [2]
    FINN RS, QIN SK, IKEDA M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma[J]. N Engl J Med, 2020, 382( 20): 1894- 1905. DOI: 10.1056/NEJMoa1915745.
    [3]
    REN ZG, XU JM, BAI YX, et al. Sintilimab plus a bevacizumab biosimilar(IBI305) versus sorafenib in unresectable hepatocellular carcinoma(ORIENT-32): A randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22( 7): 977- 990. DOI: 10.1016/S1470-2045(21)00252-7.
    [4]
    PINTER M, JAIN RK, DUDA DG. The current landscape of immune checkpoint blockade in hepatocellular carcinoma: A review[J]. JAMA Oncol, 2021, 7( 1): 113- 123. DOI: 10.1001/jamaoncol.2020.3381.
    [5]
    CHENG AL, QIN SK, IKEDA M, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma[J]. J Hepatol, 2022, 76( 4): 862- 873. DOI: 10.1016/j.jhep.2021.11.030.
    [6]
    WANG Q, JI XQ, SUN J, et al. Stereotactic body radiotherapy combined with lenvatinib with or without PD-1 inhibitors as initial treatment for unresectable hepatocellular carcinoma[J]. Int J Radiat Oncol Biol Phys, 2024. DOI: 10.1016/j.ijrobp.2024.03.035.[ Online ahead of print]
    [7]
    LIU LX, ZHANG WZ. Minimally invasive treatment strategies for hepatocellular carcinoma[J]. Chin J Dig Surg, 2024, 23( 4): 548- 553. DOI: 10.3760/cma.j.cn115610-20240202-00061.

    刘连新, 张维志. 肝细胞癌的微创治疗策略[J]. 中华消化外科杂志, 2024, 23( 4): 548- 553. DOI: 10.3760/cma.j.cn115610-20240202-00061.
    [8]
    ZHU SM, ZHANG T, ZHENG L, et al. Combination strategies to maximize the benefits of cancer immunotherapy[J]. J Hematol Oncol, 2021, 14( 1): 156. DOI: 10.1186/s13045-021-01164-5.
    [9]
    HACK SP, ZHU AX, WANG YL. Augmenting anticancer immunity through combined targeting of angiogenic and PD-1/PD-L1 pathways: Challenges and opportunities[J]. Front Immunol, 2020, 11: 598877. DOI: 10.3389/fimmu.2020.598877.
    [10]
    BENEDICT SH, YENICE KM, FOLLOWILL D, et al. Stereotactic body radiation therapy: The report of AAPM Task Group 101[J]. Med Phys, 2010, 37( 8): 4078- 4101. DOI: 10.1118/1.3438081.
    [11]
    WEN W, ZHANG Y, ZHANG H, et al. Clinical outcomes of PD-1/PD-L1 inhibitors in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis[J]. J Cancer Res Clin Oncol, 2023, 149( 3): 969- 978. DOI: 10.1007/s00432-022-04057-3.
    [12]
    ZHANG B, TAO BR, LI YT, et al. Dual immune checkpoint inhibitors or combined with anti-VEGF agents in advanced, unresectable hepatocellular carcinoma[J]. Eur J Intern Med, 2023, 111: 37- 46. DOI: 10.1016/j.ejim.2022.12.025.
    [13]
    LEE YH, TAI D, YIP C, et al. Combinational immunotherapy for hepatocellular carcinoma: Radiotherapy, immune checkpoint blockade and beyond[J]. Front Immunol, 2020, 11: 568759. DOI: 10.3389/fimmu.2020.568759.
    [14]
    PIERINI S, MISHRA A, PERALES-LINARES R, et al. Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression[J]. J Immunother Cancer, 2021, 9( 2): e001636. DOI: 10.1136/jitc-2020-001636.
    [15]
    SU K, GUO L, MA WQ, et al. PD-1 inhibitors plus anti-angiogenic therapy with or without intensity-modulated radiotherapy for advanced hepatocellular carcinoma: A propensity score matching study[J]. Front Immunol, 2022, 13: 972503. DOI: 10.3389/fimmu.2022.972503.
    [16]
    ZHU M, LIU Z, CHEN S, et al. Sintilimab plus bevacizumab combined with radiotherapy as first-line treatment for hepatocellular carcinoma with portal vein tumor thrombus: A multicenter, single-arm, phase 2 study[J]. Hepatology, 2024, 80( 4): 807- 815. DOI: 10.1097/HEP.0000000000000776.
    [17]
    SHAO GL, BAI YX, YUAN XL, et al. Ramucirumab as second-line treatment in Chinese patients with advanced hepatocellular carcinoma and elevated alpha-fetoprotein after sorafenib(REACH-2 China): A randomised, multicentre, double-blind study[J]. EClinicalMedicine, 2022, 54: 101679. DOI: 10.1016/j.eclinm.2022.101679.
    [18]
    JI XQ, XU Z, SUN J, et al. Lenvatinib with or without stereotactic body radiotherapy for hepatocellular carcinoma with portal vein tumor thrombosis: A retrospective study[J]. Radiat Oncol, 2023, 18( 1): 101. DOI: 10.1186/s13014-023-02270-z.
    [19]
    YOON SM, RYOO BY, LEE SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: A randomized clinical trial[J]. JAMA Oncol, 2018, 4( 5): 661- 669. DOI: 10.1001/jamaoncol.2017.5847.
    [20]
    HU X, CHEN RG, WEI Q, et al. The landscape of alpha fetoprotein in hepatocellular carcinoma: Where are we?[J]. Int J Biol Sci, 2022, 18( 2): 536- 551. DOI: 10.7150/ijbs.64537.
    [21]
    SUDDLE A, REEVES H, HUBNER R, et al. British Society of Gastroenterology guidelines for the management of hepatocellular carcinoma in adults[J]. Gut, 2024, 73( 8): 1235- 1268. DOI: 10.1136/gutjnl-2023-331695.
    [22]
    KIM DY, TOAN BN, TAN CK, et al. Utility of combining PIVKA-II and AFP in the surveillance and monitoring of hepatocellular carcinoma in the Asia-Pacific region[J]. Clin Mol Hepatol, 2023, 29( 2): 277- 292. DOI: 10.3350/cmh.2022.0212.
    [23]
    TIAN BW, YAN LJ, DING ZN, et al. Early alpha-fetoprotein response predicts prognosis of immune checkpoint inhibitor and targeted therapy for hepatocellular carcinoma: A systematic review with meta-analysis[J]. Expert Rev Gastroenterol Hepatol, 2023, 17( 1): 73- 83. DOI: 10.1080/17474124.2022.2156859.
    [24]
    SHAO YY, LIU TH, HSU C, et al. Early alpha-foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma[J]. Liver Int, 2019, 39( 11): 2184- 2189. DOI: 10.1111/liv.14210.
    [25]
    ZHU AX, DAYYANI F, YEN CJ, et al. Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab+bevacizumab treatment of hepatocellular carcinoma[J]. Clin Cancer Res, 2022, 28( 16): 3537- 3545. DOI: 10.1158/1078-0432.CCR-21-3275.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(3)  / Tables(3)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (104) PDF downloads(17) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return